Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy

Wake Forest University Health Sciences12 enrolled

Overview

The purpose of this research study is to determine if using a lactoferrin supplement will improve taste perception. Lactoferrin is a type of protein that is naturally produced in the body and is commonly found in saliva.

PRIMARY OBJECTIVES: I. To assess the impact of lactoferrin (bovine lactoferrin) supplementation on self-reported taste and smell disturbances in patients with colorectal cancer receiving oxaliplatin-based chemotherapy SECONDARY OBJECTIVES: I. To assess the impact of lactoferrin supplementation on the baseline lipid peroxidation byproducts in saliva in these patients as measured by the thiobarbituric acid-reactive substances (TBARs) assay. II. To assess the impact of lactoferrin supplementation on the ability of these patients to generate increased lipid peroxidation byproducts when challenged with a weak iron containing solution. III. To assess the impact of lactoferrin supplementation on self-reported general quality of life and on specific self-reported anorexia/cachexia issues in patients with established chemotherapy-induced taste disturbances. IV. To assess the incidence of vitamin D deficiency in patients with oxaliplatin-based therapy induced taste changes OUTLINE: Patients receive bovine lactoferrin orally (PO) (rinse or tablet) thrice daily (TID) for 1 month. Treatment continues in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up at 2 and 4 weeks.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Colorectal Cancer Dysgeusia Oral Complications of Chemotherapy

Interventions

questionnaire administrationOTHER

Ancillary studies

quality-of-life assessmentPROCEDURE

Ancillary studies

laboratory biomarker analysisOTHER

Correlative studies

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have histologically or cytologically confirmed colorectal carcinoma * There are no restrictions on the amount or types of prior therapy * Eligible patients must be receiving ongoing chemotherapy with an oxaliplatin containing-regimen which is planned to continue for at least one month following enrollment in this trial * Any dose or schedule of oxaliplatin administration is allowed as long as patients have self-reported taste disturbance that has either: * 1\) developed since the initiation of oxaliplatin-based therapy, or * 2\) a pre-existing, treatment-induced taste disturbance has subjectively worsened since initiating oxaliplatin-based therapy * Patients must have normal baseline self-reported taste perception prior to the development of colorectal carcinoma * Life expectancy of \>= 3 months * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients with a subjective history of an extreme dry mouth syndrome that prevents them from producing adequate amounts of saliva (approximately 2 mL in 15-20 min) * Patients known to be human immunodeficiency virus (HIV)-positive * Patients with any of the following conditions: untreated gastrointestinal reflux disease; untreated diabetes mellitus; active thrush; active oral infection; active mucositis * Patients who are known to be pregnant or who are breastfeeding are excluded

Locations (1)

Comprehensive Cancer Center of Wake Forest University

Winston-Salem, North Carolina, United States

Outcomes

Primary Outcomes

Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses

Paired-tests will be used to assess the significance of these changes. Linear regression models will be used to determine which patient covariates are associated with change. Repeated measures models will also be used to assess the changes over time using all the repeated measures and contrasts will be used to assess individual pair-wise differences. Descriptive reports will consist of summary statistics (means, standard deviations, proportions, etc.).

Time frame: Approximately 1 month

Secondary Outcomes

Effect of bovine lactoferrin on lipid peroxidation byproducts in saliva as measured by the TBARs assay

Time frame: Approximately 2 months

Malondialdehyde (MDA) concentrations before and after a ferrous iron oral rinse

Time frame: Approximately 2 months

Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire

Time frame: Approximately 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.